Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
Alberto Sánchez‐Fueyo, Antoni Rimola, Luis Grande, Josep Costa, Antoni Mas, Miguel Navasa, Isabel Cirera, Jose Maria Sánchez‐Tapias, Juan Rodés – 30 December 2003 – It is widely agreed that hepatitis B virus immunoglobulin (HBIG) should be administered for at least 12 months to patients transplanted for hepatitis B virus (HBV)‐related diseases to prevent HBV recurrence. No data are available, however, on how long this treatment should be used, and most centers currently administer HBIG on a life‐long basis.